Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238387 | 1.00 | CAPN1 (0.49) | CAPN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL30063540 | 0.87 | FFAR1 (0.49) | CAPN1 | |
| SCHEMBL27168283 | 0.87 | FFAR1 (0.49) | CAPN1 | |
| SCHEMBL27168286 | 0.87 | FFAR1 (0.49) | CAPN1 | |
| SCHEMBL12285134 | 0.86 | TSHR (0.49) | CAPN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL19296181 | 0.85 | PARP10 (0.50) | ALDH1A1KDM4ETSHRGAACTSD | |
| SCHEMBL20597773 | 0.85 | PARP10 (0.50) | ALDH1A1KDM4ETSHRGAACTSD | |
| SCHEMBL15634364 | 0.82 | LTA4H (0.56) | ALDH1A1NPC1 | |
| SCHEMBL1701896 | 0.82 | LTA4H (0.56) | ALDH1A1NPC1 | |
| SCHEMBL7270126 | 0.82 | LTA4H (0.56) | ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107213469-A | Monomethyl valine compound that can be with ligand coupling | 西雅图基因公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-103394083-B | Monomethyl valine compound that can be with ligand coupling | 西雅图基因公司 | 2017-07-18 | — | — | CN | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8557780-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120003248-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7964566-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964567-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | CAPN1 4327/4885ALDH1A1 3798/4885KDM4E 1655/4885 |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
| US-20120003248-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | CAPN1 4327/4885ALDH1A1 3798/4885KDM4E 1655/4885 |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885KDM4E 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.